<DOC>
	<DOCNO>NCT00372099</DOCNO>
	<brief_summary>Calcitonin use many year treat osteoporosis postmenopausal woman . Recent data 2 year placebo-controlled QUEST study show preservation microarchitecture measure high resolution MRI postmenopausal woman prevalent vertebral fracture baseline.This pilot study provide additional new insight mode action nasal calcitonin , structural change measure high resolution peripheral CT , comparison weight bear non weight bear bone postmenopausal woman .</brief_summary>
	<brief_title>Bone Microstructure Nasal Salmon Calcitonin Treated Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Women age 4570 Natural surgical menopause ≥ 1 year TScore 0.0 2.49 ( spine proximal femur total femoral neck measure DXA ) Osteoporosis ( Tscore ≤ 2.5 spine proximal femur total femoral neck , measure DXA ) Severe vertebral fracture , identify screen DXA assessment Any history metabolic disease , could affect bone metabolism : hyperparathyroidism , osteogenesis imperfecta , Paget 's disease , osteomalacia Thyroid disease ( receive thyroid hormone replacement , patient must euthyroid , stable dose thyroid hormone ) Impaired renal function ( estimate GFR &lt; 30 ml/min ) History previous active malignancy organ system , treat treat within past 5 year . History corticosteroids treatment 6 month , daily dosage &gt; 5 mg . BMI &lt; 18 &gt; 30 . Treatments estrogens , SERMs , tibolone , calcitonin , strontium ranelate , teriparatide PTH , oral iv bisphosphonates previous year .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Postmenopausal woman</keyword>
	<keyword>bone microarchitecture</keyword>
	<keyword>peripheral quantitative micro-CT</keyword>
	<keyword>salmon calcitonin</keyword>
</DOC>